Roche: FDA OKs drug for children chronic arthritis
(CercleFinance.com) - The US Food and Drug Administration has approved a subcutaneous formulation of Roche's Actemra for the treatment of active systemic juvenile idiopathic arthritis, a chronic disease affecting children, the Swiss company said late on Thursday.
The FDA has approved the product for the treatment of patients of two years and above, Roche said.
Actemra can be taken alone or in combination with methotrexate, it added.
In 2011, the FDA approved the intravenous formulation of Actemra for patients of two years and above who have active systemic juvenile idiopathic arthritis.
It is estimated that juvenile idiopathic arthritis affects nearly 300,000 children in the US, of which active systemic juvenile idiopathic arthritis accounts for around 10 percent.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The FDA has approved the product for the treatment of patients of two years and above, Roche said.
Actemra can be taken alone or in combination with methotrexate, it added.
In 2011, the FDA approved the intravenous formulation of Actemra for patients of two years and above who have active systemic juvenile idiopathic arthritis.
It is estimated that juvenile idiopathic arthritis affects nearly 300,000 children in the US, of which active systemic juvenile idiopathic arthritis accounts for around 10 percent.
Copyright (c) 2018 CercleFinance.com. All rights reserved.